Loading organizations...
Key people at Orphalan.
Orphalan is an international pharmaceutical company dedicated to developing and commercializing orphan drugs. It identifies, advances, and provides access to innovative treatments for rare and debilitating diseases. Its primary offering, a trientine tetrahydrochloride therapy branded Cuprior® or Cuvrior®, treats Wilson disease and is distributed across over 30 countries.
Established in Paris in 2011, Orphalan emerged from the insight that many rare diseases lack adequate therapeutic options or suffer from significant complications. This core realization drives the company’s patient-centric approach, delivering impactful, novel therapies for conditions where existing medical solutions fall short.
Orphalan serves global rare disease patients, fostering strong partnerships within the medical community. Its vision is to transform care, ensuring individuals gain access to innovative treatments that enhance their quality of life. Orphalan prioritizes collaborative, evidence-based research, believing all patients merit effective, accessible therapeutic advancements.
Key people at Orphalan.
Orphalan is a privately owned international biopharmaceutical company founded in 2011, specializing in the development and commercialization of orphan drugs for rare diseases.[1][2][3] Its flagship product, Cuvrior® (trientine tetrahydrochloride, also branded as Cuprior® in Europe and other regions), treats Wilson's disease—a rare genetic disorder causing toxic copper accumulation—offering a best-in-class alternative to existing therapies with fewer side effects and easier handling, such as room-temperature stability.[1][3][4] Orphalan serves patients worldwide, particularly those with rare neurological, oncological, and pediatric conditions, addressing unmet needs through a patient-centered approach that emphasizes accessibility, global commercialization, and partnerships with healthcare professionals and nonprofits.[1][4] The company has achieved regulatory approvals in over 38 countries, including FDA approval in 2022 and China NMPA in 2024, with marketing in 28+ countries, bolstered by its recent December 2025 acquisition of Orphelia Pharma to expand into pediatric neurology and oncology.[1][3][4]
Orphalan was founded in 2011 in Paris, France, emerging from a collaboration between AGEPS (a French hospital pharmacy group) and Hôpital Lariboisière to reposition existing drugs for orphan diseases by leveraging untapped academic research and clinical data.[1][3] The company's initial focus was Wilson's disease, where current treatments like penicillamine had limitations such as side effects and refrigeration needs; Orphalan developed trientine tetrahydrochloride as a superior option.[3] Early traction came from launching Cuprior® in Europe in 2015, supported by Advent Life Sciences as the sole Series A investor in 2015.[3][4] Leadership evolved with Dr. Naseem Amin becoming CEO in June 2017; his background includes roles at Arix Bioscience, Advent Life Sciences, Smith & Nephew, Biogen Idec, Genzyme, and Baxter, bringing expertise in life sciences R&D, business development, and venture capital.[2] Pivotal moments include FDA approval of Cuvrior™ in 2022, China approval in 2024, and the 2025 Orphelia Pharma acquisition, solidifying its global footprint.[1][3]
Orphalan rides the orphan drug trend, where market forces favor high-margin therapies for rare diseases due to regulatory incentives like Orphan Drug Designation, expedited approvals, and 7-10 year market exclusivity, amid a global rise in diagnosed rare conditions.[1][2][3] Timing is ideal post-2020s biotech boom, with growing emphasis on precision medicine and gene-related disorders like Wilson's disease (affecting 1 in 30,000).[3] Favorable dynamics include untapped emerging markets (e.g., China approval) and partnerships addressing access gaps in developing countries, countering traditional pharma's neglect of low-volume diseases.[1][4][5] Orphalan influences the ecosystem by pioneering drug repositioning, accelerating therapies via academic collaborations, and expanding via M&A like Orphelia, setting a model for agile biopharma players in Europe's rare disease space.[1][3]
Orphalan's momentum—fueled by Cuvrior®'s global rollout, recent acquisition, and patent portfolio—positions it for accelerated growth in orphan drugs, potentially targeting 50+ countries and new indications in pediatric oncology/neurology.[1][2][3] Trends like AI-driven drug discovery, expanded orphan incentives, and rising rare disease awareness will shape its path, enabling pipeline diversification beyond Wilson's.[3][5] Its influence may evolve from niche player to European rare disease leader with global scale, prioritizing underserved patients; watch for further M&A or partnerships to sustain innovation in this high-need, high-reward sector. This builds on its core mission: transforming rare disease care through accessible, innovative therapies.[1][4]
